These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines. Rubner Y; Muth C; Strnad A; Derer A; Sieber R; Buslei R; Frey B; Fietkau R; Gaipl US Radiat Oncol; 2014 Mar; 9(1):89. PubMed ID: 24678590 [TBL] [Abstract][Full Text] [Related]
4. Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma. Wang X; Guo G; Guan H; Yu Y; Lu J; Yu J J Exp Clin Cancer Res; 2019 Feb; 38(1):87. PubMed ID: 30777100 [TBL] [Abstract][Full Text] [Related]
5. Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kγ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cells. Miyazaki T; Ishikawa E; Matsuda M; Sugii N; Kohzuki H; Akutsu H; Sakamoto N; Takano S; Matsumura A Brain Tumor Pathol; 2020 Apr; 37(2):41-49. PubMed ID: 31980975 [TBL] [Abstract][Full Text] [Related]
6. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells. Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502 [TBL] [Abstract][Full Text] [Related]
7. Detailed Stoll E; Hader M; Rückert M; Weissmann T; Lettmaier S; Putz F; Hecht M; Fietkau R; Rosin A; Frey B; Gaipl US Int J Hyperthermia; 2022; 39(1):796-805. PubMed ID: 35676615 [TBL] [Abstract][Full Text] [Related]
8. MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT. Zhao C; Guo R; Guan F; Ma S; Li M; Wu J; Liu X; Li H; Yang B Sci Rep; 2020 Jun; 10(1):9471. PubMed ID: 32528036 [TBL] [Abstract][Full Text] [Related]
9. PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential. Yang T; Kong Z; Ma W Hum Vaccin Immunother; 2021 Feb; 17(2):546-553. PubMed ID: 32643507 [TBL] [Abstract][Full Text] [Related]
10. Hypofractionated Radiotherapy Upregulates Several Immune Checkpoint Molecules in Head and Neck Squamous Cell Carcinoma Cells Independently of the HPV Status While ICOS-L Is Upregulated Only on HPV-Positive Cells. Wimmer S; Deloch L; Hader M; Derer A; Grottker F; Weissmann T; Hecht M; Gostian AO; Fietkau R; Frey B; Gaipl US Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502022 [TBL] [Abstract][Full Text] [Related]
11. Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR. Vaidya KS; Mitten MJ; Zelaya-Lazo AL; Oleksijew A; Alvey C; Falls HD; Mishra S; Palma J; Ansell P; Phillips AC; Reilly EB; Anderson M; Boghaert ER J Neurooncol; 2021 Apr; 152(2):233-243. PubMed ID: 33517558 [TBL] [Abstract][Full Text] [Related]
12. EGFR-ERK pathway regulates CSN6 to contribute to PD-L1 expression in glioblastoma. Su L; Guo W; Lou L; Nie S; Zhang Q; Liu Y; Chang Y; Zhang X; Li Y; Shen H Mol Carcinog; 2020 May; 59(5):520-532. PubMed ID: 32134157 [TBL] [Abstract][Full Text] [Related]
13. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation. Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094 [No Abstract] [Full Text] [Related]
14. Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions. Maghrouni A; Givari M; Jalili-Nik M; Mollazadeh H; Bibak B; Sadeghi MM; Afshari AR; Johnston TP; Sahebkar A Int Immunopharmacol; 2021 Apr; 93():107403. PubMed ID: 33581502 [TBL] [Abstract][Full Text] [Related]
15. Combination of p38 MAPK inhibitor with PD-L1 antibody effectively prolongs survivals of temozolomide-resistant glioma-bearing mice via reduction of infiltrating glioma-associated macrophages and PD-L1 expression on resident glioma-associated microglia. Dang W; Xiao J; Ma Q; Miao J; Cao M; Chen L; Shi Y; Yao X; Yu S; Liu X; Cui Y; Zhang X; Bian X Brain Tumor Pathol; 2021 Jul; 38(3):189-200. PubMed ID: 34231121 [TBL] [Abstract][Full Text] [Related]
16. NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma. Yahyanejad S; King H; Iglesias VS; Granton PV; Barbeau LM; van Hoof SJ; Groot AJ; Habets R; Prickaerts J; Chalmers AJ; Eekers DB; Theys J; Short SC; Verhaegen F; Vooijs M Oncotarget; 2016 Jul; 7(27):41251-41264. PubMed ID: 27183910 [TBL] [Abstract][Full Text] [Related]
17. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme. Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285 [TBL] [Abstract][Full Text] [Related]
18. Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma. Yin J; Zeng A; Zhang Z; Shi Z; Yan W; You Y EBioMedicine; 2019 Apr; 42():238-251. PubMed ID: 30917935 [TBL] [Abstract][Full Text] [Related]